Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010852080
Biotechnology & Medical Research
Sales 2024 * | 37.9M 14.23B | Sales 2025 * | 35.29M 13.25B | Capitalization | 173M 64.88B |
---|---|---|---|---|---|
Net income 2024 * | -13M -4.88B | Net income 2025 * | -29M -10.89B | EV / Sales 2024 * | 4.56 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.9 x |
P/E ratio 2024 * |
-15.3
x | P/E ratio 2025 * |
-7.37
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-12-31 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 22-10-31 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 17-10-01 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 18-06-10 |
Gilead Halevy
BRD | Director/Board Member | 57 | 18-06-10 |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |